Clinical trial
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
NCT07047716
Study timeline
Study start (actual)2025-07-22Date precision: day
Registry last updated2026-08-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HIV Pre-exposure Prophylaxisunresolved
Interventions
Lenacapavir InjectionDRUG · verified · RxNorm: lenacapavir Injection
Sponsors & collaborators
Gilead Scienceslead sponsor
Mapped research locations
Los AngelesCalifornia, United States4ChicagoIllinois, United States2PhiladelphiaPennsylvania, United States2AtlantaGeorgia, United States2Washington D.C.District of Columbia, United States2New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1BaltimoreMaryland, United States1MiamiFlorida, United States1San FranciscoCalifornia, United States1SeattleWashington, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07047716 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.